The promise of mitochondria-based therapeutics for NASH

Liver with signs of nonalcoholic fatty liver disease. Image courtesy of NIH.

Although nonalcoholic steatohepatitis (NASH) is one of the most common types of chronic liver disease in the U.S., it is a disease that is unfamiliar to many Americans. Despite this, its prevalence is increasing, and by some estimates, 27 million Americans will be living with NASH by 2030.

NASH is a progressive condition that starts with excess fat buildup in the liver, leading to inflammation and liver damage. While the cause of NASH is unknown, it is associated with a broader set of metabolic disorders. Important risk factors include elevated triglyceride or cholesterol levels, type 2 diabetes, high blood pressure and obesity, particularly with body fat concentrated around the waist. NASH is also more prevalent in certain ethnic groups, including Asian and Hispanic populations. While there are generally no symptoms until late in t…

Read more
  • 0